Figure 3.
Low-dose, prolonged treatment with deferoxamine (DFO) does not induce erythropoietin (EPO) or vascular endothelial growth factor (VEGF) protein abundance in brain as measured by enzyme-linked immunosorbent assay (ELISA) (two-way analysis of variance (ANOVA) with Bonferroni's posttest analysis, n=3 mice in each group).